Brzóska-Konkol Ewa, Remberk Barbara, Papasz-Siemienuk Anna
Institute of Psychiatry and Neurology, Warsaw, Poland.
Postep Psychiatr Neurol. 2022 Mar;31(1):25-34. doi: 10.5114/ppn.2022.115244. Epub 2022 Apr 5.
The prevalence of autism spectrum disorder (ASD) has increased tenfold over the last 40 years and the World Health Organization (WHO) has placed it alongside other globally occurring common illnesses, such as cancer, cardiovascular disorders and diabetes. As there are yet no effective methods for treating ASD, the most frequently used therapeutic interventions are psychological, psychosocial, rehabilitation and developmental support, which in combination aim to support patients and their families. Early intervention improves the prognosis, but usually a cure is impossible. Patient's lives are often burdened with social difficulties in contact with their families, peers and in education, particularly when other disorders, diseases or intellectual impairment are present, leading to undesirable behaviours, including aggression or self-aggression. Aim of the study was to review the literature available, so as to determine the effectiveness of probiotics used for treating core and accompanying symptoms of autism in patients diagnosed with ASD, with a particular focus on children and adolescents.
The randomised clinical trials available on the clinicaltrials.gov register (accessed on June 27, 2021) and the PubMed database (search: probiotic + autism, probiotic + ASD, probiotic + Asperger syndrome, probiotic + pervasive developmental disorder, randomised controlled trial filter) have been analysed in the present study. All studies were included, without any operational time limit. The same PubMed search was also re-run for open-label trials. Out of the 140 papers found, five were open-trials. We also supplemented our study by additionally analysing the studies cited by the latest papers on probiotics in autism.
There are still no consistent outcomes in studies on the use of probiotics in children and adolescents with ASD, and the scope of existing studies is limited. Nevertheless, the authors considered it worthwhile to explore whether probiotic interventions can indeed reduce the severity of ASD-related symptoms and behaviours. Further studies are required on specific indications, duration of treatment and the effectiveness of interventions in the defined problem areas.
在过去40年里,自闭症谱系障碍(ASD)的患病率增长了10倍,世界卫生组织(WHO)已将其与其他全球常见疾病,如癌症、心血管疾病和糖尿病相提并论。由于目前尚无治疗ASD的有效方法,最常用的治疗干预措施是心理、心理社会、康复和发育支持,这些措施综合起来旨在为患者及其家庭提供支持。早期干预可改善预后,但通常无法治愈。患者的生活常常因在与家人、同龄人接触以及教育方面存在社交困难而负担沉重,尤其是当存在其他障碍、疾病或智力障碍时,会导致包括攻击或自我攻击在内的不良行为。本研究的目的是回顾现有文献,以确定益生菌用于治疗被诊断为ASD患者的自闭症核心症状及伴随症状的有效性,特别关注儿童和青少年。
本研究分析了clinicaltrials.gov注册平台(于2021年6月27日访问)以及PubMed数据库(检索词:益生菌+自闭症、益生菌+ASD、益生菌+阿斯伯格综合征、益生菌+广泛性发育障碍、随机对照试验筛选器)上的随机临床试验。纳入了所有研究,没有任何操作时间限制。还针对开放标签试验重新进行了相同的PubMed检索。在找到的140篇论文中,有5篇是开放试验。我们还通过额外分析自闭症领域最新益生菌论文所引用的研究来补充我们的研究。
关于益生菌在患有ASD的儿童和青少年中的应用研究,目前仍没有一致的结果,现有研究的范围也有限。尽管如此,作者认为探索益生菌干预是否真的能减轻与ASD相关的症状和行为的严重程度是值得的。需要针对特定适应症、治疗持续时间以及在明确问题领域的干预效果进行进一步研究。